ASTAL LABORATORIES LIMITED — M&A Activity 2025

Oct 10, 2025

ASTAL LABORATORIES LIMITED

(Formerly known as MACRO INTERNATIONAL LIMITED) CIN: L74120UP1993PLC015605

==> picture [69 x 56] intentionally omitted <==

Astal Laboratories Limited

Regd. Office: Office No. B7, A-40, Sector 4, Noida, Gautam Buddha Nagar, Uttar Pradesh 201301 Corporate Office: House No 4-50 1 Sy No 134 132 Block B 8th Floor Flat No 801, The Platina Kondapur Road, Gachibowli, K.V.Rangareddy, Seri Lingampally, Telangana, India, 500032 SCRIP CODE: 512600, SECURITY ID: ASTALLTD, BSE India Email: meil100@rediffmail.com: Mob. No: 6302730973, Website: h ttps://astallabs.com/

Date: 10[th] October, 2025

To, The Deputy Manager (Department of Corporate Services) BSE Limited P. J. Towers Dalal Street, Fort, Mumbai- 400001

Sub: Intimation Under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Ref: Scrip Code: 512600 Security Id: ASTALLTD

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations”), we wish to inform you that the Board of Directors of the Company at its meeting held on Thursday, 9[th] October, 2025 approved the proposed acquisition of 100% equity shares of Sriven Pharmachem India Private Limited (“SPIPL”/ “Target Company”), from the existing shareholder of “SPIPL”, which shall be subject to shareholders’ approval to discharge the Consideration through a share swap at a ratio of 1:1 (i.e. 1 equity share of the Company to be issued and allotted against 1 equity share held by the shareholders of SPIPL).

The details as required under SEBI Listing Regulations read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 are enclosed herewith as “Annexure A”

The meeting commenced at 05.00 p.m. and concluded at 09:15 p.m.

The above intimation is given to you for your record, kindly take the note of the same.

Thanking You,

Yours faithfully,

For Astal Laboratories Limited

MAHENDR Digitally signed by MAHENDRA KUMAR A KUMAR Date: 2025.10.10 13:44:02 +05'30'

Mahendra Kumar (Company Secretary & Compliance officer) Membership No.: A71224

==> picture [69 x 56] intentionally omitted <==

Astal Laboratories Limited

ASTAL LABORATORIES LIMITED

(Formerly known as MACRO INTERNATIONAL LIMITED) CIN: L74120UP1993PLC015605

Regd. Office: Office No. B7, A-40, Sector 4, Noida, Gautam Buddha Nagar, Uttar Pradesh 201301 Corporate Office: House No 4-50 1 Sy No 134 132 Block B 8th Floor Flat No 801, The Platina Kondapur Road, Gachibowli, K.V.Rangareddy, Seri Lingampally, Telangana, India, 500032 SCRIP CODE: 512600, SECURITY ID: ASTALLTD, BSE India Email: meil100@rediffmail.com: Mob. No: 6302730973, Website: h ttps://astallabs.com/

ANNEXURE-1

Detailed disclosure as required under Regulation 30 of SEBI (LODR) Regulations, 2015 read with SEBI Master Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024:

a) Name of the target entity, i) Name of the Target Company: Sriven Pharmachem India Private details in brief such as size, Limited (‘SPIPL’/ ‘Target Company’) turnover etc.; ii) Details of the Target Company: Sriven Pharmachem India Private Limited is engaged in Developing and producing specified high profile Drug Intermediates and Specialty Chemicals. iii) April- March 2025 Turnover: Rs. 1,027,009,061.00/Net Profit: Rs. 6,991,744.00/- iv) Authorised Share Capital of the Target Company: Rs. 31,00,00,000/- divided into 3,10,00,000 Equity Shares of Rs. 10/each. v) Paid-up share capital of the Target Company: Rs. 30,45,81,870/- divided into 3,04,58,187 Equity Shares of Rs. 10/each. b) Whether the acquisition The proposed acquisition would not fall within Related Party Transaction.[Refer Note ] would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm’s length";

c) Industry to which the entity Pharmaceutical Industry being acquired belongs;

ASTAL LABORATORIES LIMITED

(Formerly known as MACRO INTERNATIONAL LIMITED) CIN: L74120UP1993PLC015605

==> picture [69 x 56] intentionally omitted <==

Astal Laboratories Limited

Regd. Office: Office No. B7, A-40, Sector 4, Noida, Gautam Buddha Nagar, Uttar Pradesh 201301 Corporate Office: House No 4-50 1 Sy No 134 132 Block B 8th Floor Flat No 801, The Platina Kondapur Road, Gachibowli, K.V.Rangareddy, Seri Lingampally, Telangana, India, 500032 SCRIP CODE: 512600, SECURITY ID: ASTALLTD, BSE India Email: meil100@rediffmail.com: Mob. No: 6302730973, Website: h ttps://astallabs.com/

d) Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	The acquisition is of strategic nature and will help Astal Laboratories Limited to expand its products offering. The acquisition aligns with Astal Laboratories Limited’s long-term vision of becoming a fully integrated pharmaceutical manufacturing company. It will deliver both immediate and sustained benefits through scale, synergy, and diversification, thereby contributing to improved operational strength, profitability, and shareholder value.
e) Brief details of any governmental or regulatory approvals required for the acquisition;	No
f) Indicative time period for completion of the acquisition;	The Acquisition shall be completed within the 15 days from the approval of Members of the Company by passing the special resolution or receipt of in principle approval of the Stock Exchange i.e. BSE whichever is later.
g) Nature of consideration - whether cash consideration or share swap and details of the same;	The consideration for the acquisition of equity shares of SPIPL (the "Target Company") shall be discharged through a share swap at a ratio of 1:1_(i.e. 1 equity share of the Company to be issued and allotted_ _against 1 equity share held by the shareholders of SPIPL),_as detailed below: Share Swap (Non-Cash Consideration):The Company shall issue and allot 3,04,58,187 equity shares on a preferential basis to the shareholders of SPIPL towards the acquisition of 3,04,58,187 equity shares, constituting 100% of the total outstanding equity share capital of the SPIPL/ Target Company.
h) Cost of acquisition or the price at which the shares are acquired;	Rs. 277,16,95,017/-.
i) Percentage of shareholding /control acquired and / or number of shares acquired;	Astal Laboratories Limited (‘the Company’) has agreed to acquire 100% Equity shares of the Target Company. Astal Laboratories Limited shall become Holding Company of the Target Company upon acquisition of shares of the Target Company.
j) Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any	i)Line of Business: Manufacturing of active pharmaceutical ingredients (APIs) and intermediates. ii)Date of Incorporation: 5thMarch, 2015 iii)Turnover of last 3 years: April- March 2023: Rs. 35,84,82,600.00/- April- March 2024: Rs. 1,007,591,448.00/-

==> picture [69 x 56] intentionally omitted <==

Astal Laboratories Limited

ASTAL LABORATORIES LIMITED

(Formerly known as MACRO INTERNATIONAL LIMITED) CIN: L74120UP1993PLC015605

Regd. Office: Office No. B7, A-40, Sector 4, Noida, Gautam Buddha Nagar, Uttar Pradesh 201301 Corporate Office: House No 4-50 1 Sy No 134 132 Block B 8th Floor Flat No 801, The Platina Kondapur Road, Gachibowli, K.V.Rangareddy, Seri Lingampally, Telangana, India, 500032 SCRIP CODE: 512600, SECURITY ID: ASTALLTD, BSE India Email: meil100@rediffmail.com: Mob. No: 6302730973, Website: h ttps://astallabs.com/

	other significant information (in brief);	April- March 2025: Rs. 1,027,009,061.00/- iv)Profit of last 3 years: April- March 2023: Rs. 1,19,96,816.00/- April- March 2024: Rs. 49,129,976.00/- April- March 2025: Rs. 6,991,744.00/- v)Country in which the acquired entity has presence: India

Note:

Mr. Sudheer Karna Kankanala, the Director of Astal Laboratories Limited (“the Company), is also a shareholder of Sriven Pharmachem India Private Limited. Further, since this Acquisition is for consideration other than cash, he is a Proposed Allottee for the Preferential Issue.

For Astal Laboratories Limited

MAHENDR Digitally signed by MAHENDRA KUMAR A KUMAR Date: 2025.10.10 13:44:32 +05'30'

Mahendra Kumar (Company Secretary & Compliance Officer) Membership No.: A71224